



Clinical trial results:

An open-label, single arm, multi-centre, phase II study investigating safety, tolerability, efficacy, pharmacodynamics and pharmacokinetics of imlifidase (IdeS) in patients with Guillain-Barré Syndrome (GBS), in comparison with matched control patients

Summary

| | |
|--------------------------|------------------|
| EudraCT number | 2018-001059-12 |
| Trial protocol | GB NL |
| Global end of trial date | 27 February 2024 |

Results information

| | |
|--------------------------------|---------------|
| Result version number | v1 (current) |
| This version publication date | 12 March 2025 |
| First version publication date | 12 March 2025 |

Trial information

Trial identification

| | |
|-----------------------|----------------|
| Sponsor protocol code | 15-HMedIdeS-09 |
|-----------------------|----------------|

Additional study identifiers

| | |
|------------------------------------|-------------|
| ISRCTN number | - |
| ClinicalTrials.gov id (NCT number) | NCT03943589 |
| WHO universal trial number (UTN) | - |

Notes:

Sponsors

| | |
|------------------------------|---|
| Sponsor organisation name | Hansa Biopharma AB |
| Sponsor organisation address | Scheelevägen 22, Lund, Sweden, 223 63 |
| Public contact | Clinical Operation Department, Hansa Biopharma AB, 46 46165670, info@hansabiopharma.com |
| Scientific contact | Clinical Operation Department, Hansa Biopharma AB, 46 46165670, info@hansabiopharma.com |

Notes:

Paediatric regulatory details

| | |
|--|----|
| Is trial part of an agreed paediatric investigation plan (PIP) | No |
| Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? | No |
| Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? | No |

Notes:

Results analysis stage

| | |
|--|------------------|
| Analysis stage | Final |
| Date of interim/final analysis | 03 July 2024 |
| Is this the analysis of the primary completion data? | Yes |
| Primary completion date | 27 February 2024 |
| Global end of trial reached? | Yes |
| Global end of trial date | 27 February 2024 |
| Was the trial ended prematurely? | No |

Notes:

General information about the trial

Main objective of the trial:

Assess safety and tolerability of imlifidase in combination with standard IVIg treatment in GBS subjects

Protection of trial subjects:

Details of the goals of the research and the risk and benefits of the protocol were reviewed with each potential study subject.

In the event of adverse events from the study, full resources of the hospital were available to intervene as medically necessary.

Physicians expert in the care of patients with GBS were responsible for the patients' care at each site.

To mitigate the risk of infections all patients received prophylactic treatment with antibiotics administered orally once daily for 14 days starting before imlifidase infusion on Day 1.

In order to reduce the risk of infusion reaction, a phenomenon that may occur with infusion of proteins, premedication with methylprednisolone (IV) and antihistamine (oral) were given to all patients before the imlifidase infusion.

As participation in the trial delayed the commencement of standard IVIg treatment, a patient could, if the GBS symptoms worsened very quickly during the first 24 hours after imlifidase administration, be given PLEX to manage the rapid progression of GBS and to remove any remaining imlifidase before initiating IVIg treatment according to standard of care. This decision was made at the discretion of the investigator.

Background therapy:

Standard of care IVIg infusions for 5 consecutive days at 0.4 g/kg, starting on Day 3. IVIg was given at least 48 hours after imlifidase administration and within 14 days of onset of weakness. Premedication before first dose of IVIg was given according to local clinical standard.

Evidence for comparator:

-

| | |
|---|------------------|
| Actual start date of recruitment | 12 November 2019 |
| Long term follow-up planned | No |
| Independent data monitoring committee (IDMC) involvement? | Yes |

Notes:

Population of trial subjects

Subjects enrolled per country

| | |
|--------------------------------------|-------------------|
| Country: Number of subjects enrolled | Netherlands: 1 |
| Country: Number of subjects enrolled | United Kingdom: 3 |
| Country: Number of subjects enrolled | France: 26 |
| Worldwide total number of subjects | 30 |
| EEA total number of subjects | 27 |

Notes:

| Subjects enrolled per age group | |
|---|----|
| In utero | 0 |
| Preterm newborn - gestational age < 37 wk | 0 |
| Newborns (0-27 days) | 0 |
| Infants and toddlers (28 days-23 months) | 0 |
| Children (2-11 years) | 0 |
| Adolescents (12-17 years) | 0 |
| Adults (18-64 years) | 18 |
| From 65 to 84 years | 12 |
| 85 years and over | 0 |

Subject disposition

Recruitment

Recruitment details:

Patients were recruited between 12-NOV-2019 and 02-MAR-2023.

Pre-assignment

Screening details:

A total of 31 patients were screened. Thirty (30) patients were enrolled and dosed with imlifidase.

Period 1

| | |
|------------------------------|--------------------------------|
| Period 1 title | Overall trial (overall period) |
| Is this the baseline period? | Yes |
| Allocation method | Not applicable |
| Blinding used | Not blinded |

Blinding implementation details:

N/A

Arms

| | |
|-----------|-------------------------------------|
| Arm title | All patients intended to be treated |
|-----------|-------------------------------------|

Arm description: -

| | |
|--|---------------------------------------|
| Arm type | Experimental |
| Investigational medicinal product name | Imlifidase |
| Investigational medicinal product code | |
| Other name | IdeS, IgG endopeptidase |
| Pharmaceutical forms | Concentrate for solution for infusion |
| Routes of administration | Intravenous use |

Dosage and administration details:

A dose of 0.25 mg/kg was administered as an IV infusion over 30 minutes.

| | |
|---------------------------------------|-------------------------------------|
| Number of subjects in period 1 | All patients intended to be treated |
| Started | 30 |
| Completed | 28 |
| Not completed | 2 |
| Adverse event, serious fatal | 1 |
| Diagnosed with encephalomyelitis | 1 |

Baseline characteristics

Reporting groups

| | |
|--------------------------------|---------------|
| Reporting group title | Overall trial |
| Reporting group description: - | |

| Reporting group values | Overall trial | Total | |
|--|---------------|-------|--|
| Number of subjects | 30 | 30 | |
| Age categorical | | | |
| Units: Subjects | | | |
| In utero | 0 | 0 | |
| Preterm newborn infants (gestational age < 37 wks) | 0 | 0 | |
| Newborns (0-27 days) | 0 | 0 | |
| Infants and toddlers (28 days-23 months) | 0 | 0 | |
| Children (2-11 years) | 0 | 0 | |
| Adolescents (12-17 years) | 0 | 0 | |
| Adults (18-64 years) | 18 | 18 | |
| From 65-84 years | 12 | 12 | |
| 85 years and over | 0 | 0 | |
| Age continuous | | | |
| Units: years | | | |
| arithmetic mean | 55.6 | | |
| standard deviation | ± 18.5 | - | |
| Gender categorical | | | |
| Units: Subjects | | | |
| Female | 14 | 14 | |
| Male | 16 | 16 | |

Subject analysis sets

| | |
|----------------------------|---------------|
| Subject analysis set title | FAS |
| Subject analysis set type | Full analysis |

Subject analysis set description:

All dosed patients having a confirmed GBS diagnosis, i.e., patients re-evaluated and having change in diagnosis (incorrectly diagnosed with GBS at trial entry) were excluded.

Used for presentation of efficacy endpoints.

| | |
|----------------------------|--------------------|
| Subject analysis set title | PK/PD |
| Subject analysis set type | Sub-group analysis |

Subject analysis set description:

All dosed patients, with at least one PK or PD data point available post-baseline.

Used for presentation of PK and PD endpoints.

| | |
|----------------------------|---------------------|
| Subject analysis set title | Safety analysis set |
| Subject analysis set type | Safety analysis |

Subject analysis set description:

All dosed patients.

Used for presentation of safety endpoints

| Reporting group values | FAS | PK/PD | Safety analysis set |
|---|--------|--------|---------------------|
| Number of subjects | 27 | 30 | 30 |
| Age categorical | | | |
| Units: Subjects | | | |
| In utero | 0 | 0 | 0 |
| Preterm newborn infants (gestational age < 37 wks) | 0 | 0 | 0 |
| Newborns (0-27 days) | 0 | 0 | 0 |
| Infants and toddlers (28 days-23 months) | 0 | 0 | 0 |
| Children (2-11 years) | 0 | 0 | 0 |
| Adolescents (12-17 years) | 0 | 0 | 0 |
| Adults (18-64 years) | 17 | 18 | 18 |
| From 65-84 years | 10 | 12 | 12 |
| 85 years and over | 0 | 0 | 0 |
| Age continuous | | | |
| Units: years | | | |
| arithmetic mean | 54.8 | 55.6 | 55.6 |
| standard deviation | ± 19.3 | ± 18.5 | ± 18.5 |
| Gender categorical | | | |
| Units: Subjects | | | |
| Female | 13 | 14 | 14 |
| Male | 14 | 16 | 16 |

End points

End points reporting groups

| | |
|--|-------------------------------------|
| Reporting group title | All patients intended to be treated |
| Reporting group description: - | |
| Subject analysis set title | FAS |
| Subject analysis set type | Full analysis |
| Subject analysis set description: | |
| All dosed patients having a confirmed GBS diagnosis, i.e., patients re-evaluated and having change in diagnosis (incorrectly diagnosed with GBS at trial entry) were excluded. Used for presentation of efficacy endpoints. | |
| Subject analysis set title | PK/PD |
| Subject analysis set type | Sub-group analysis |
| Subject analysis set description: | |
| All dosed patients, with at least one PK or PD data point available post-baseline. Used for presentation of PK and PD endpoints. | |
| Subject analysis set title | Safety analysis set |
| Subject analysis set type | Safety analysis |
| Subject analysis set description: | |
| All dosed patients. Used for presentation of safety endpoints | |

Primary: GBS disability score - Able to walk independently

| | |
|--------------------------|--|
| End point title | GBS disability score - Able to walk independently ^[1] |
| End point description: | |
| End point type | Primary |
| End point timeframe: | |
| From Baseline to Day 360 | |

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Not applicable, this was a single arm study.

| End point values | FAS | | | |
|-----------------------------|----------------------|--|--|--|
| Subject group type | Subject analysis set | | | |
| Number of subjects analysed | | | | |
| Units: Patients | | | | |
| Baseline | 0 | | | |
| Day 2 | 4 | | | |
| Day 3 | 5 | | | |
| Day 4 | 9 | | | |
| Day 5 | 9 | | | |
| Day 6 | 9 | | | |
| Day 7 | 10 | | | |
| Day 8 | 10 | | | |
| Day 15 | 13 | | | |
| Day 29 | 14 | | | |
| Day 57 | 18 | | | |
| Day 92 | 20 | | | |
| Day 180 | 23 | | | |
| Day 360 | 24 | | | |

Statistical analyses

No statistical analyses for this end point

Primary: GBS disability score - Able to run

| | |
|-----------------|---|
| End point title | GBS disability score - Able to run ^[2] |
|-----------------|---|

End point description:

| | |
|----------------|---------|
| End point type | Primary |
|----------------|---------|

End point timeframe:

From Baseline to Day 360

Notes:

[2] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Not applicable, this was a single arm study.

| End point values | FAS | | | |
|-----------------------------|----------------------|--|--|--|
| Subject group type | Subject analysis set | | | |
| Number of subjects analysed | 27 | | | |
| Units: Patients | | | | |
| Baseline | 0 | | | |
| Day 2 | 0 | | | |
| Day 3 | 0 | | | |
| Day 4 | 0 | | | |
| Day 5 | 1 | | | |
| Day 6 | 1 | | | |
| Day 7 | 2 | | | |
| Day 8 | 4 | | | |
| Day 15 | 5 | | | |
| Day 29 | 9 | | | |
| Day 57 | 11 | | | |
| Day 92 | 15 | | | |
| Day 180 | 17 | | | |
| Day 360 | 18 | | | |

Statistical analyses

No statistical analyses for this end point

Primary: GBS DS - Time to improve by at least 1 grade

| | |
|-----------------|---|
| End point title | GBS DS - Time to improve by at least 1 grade ^[3] |
|-----------------|---|

End point description:

The GBS disability score is a scoring system used to assess the status of the patients with GBS. The score consists of the following grades: 0=Healthy, 1= Minor symptoms and capable of running, 2=Able to walk independently 10 meters of more but unable to run, 3=Able to walk more than 10 meters across an open space with help, 4=Beridden or chair bound, 5=Needing mechanical ventilation, 6=Dead

| | |
|----------------|---------|
| End point type | Primary |
|----------------|---------|

End point timeframe:

From Baseline to Day 360

Notes:

[3] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Not applicable, this was a single arm study.

| End point values | FAS | | | |
|-------------------------------------|----------------------|--|--|--|
| Subject group type | Subject analysis set | | | |
| Number of subjects analysed | 27 | | | |
| Units: Days | | | | |
| median (full range (min-max)) | | | | |
| Time to improve by at least 1 grade | 6.0 (3.0 to 16.0) | | | |

Statistical analyses

No statistical analyses for this end point

Primary: MRC sum score over time

| | |
|-----------------|--|
| End point title | MRC sum score over time ^[4] |
|-----------------|--|

End point description:

The Medical Research Council (MRC) scale is a commonly used tool for assessing muscle strength. The resulting MRC sum score ranges from 60 (normal) to 0 (quadriplegic).

| | |
|----------------|---------|
| End point type | Primary |
|----------------|---------|

End point timeframe:

From Baseline to Day 180

Notes:

[4] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Not applicable, this was a single arm study.

| End point values | FAS | | | |
|--------------------------------------|----------------------|--|--|--|
| Subject group type | Subject analysis set | | | |
| Number of subjects analysed | | | | |
| Units: Score | | | | |
| arithmetic mean (standard deviation) | | | | |
| Baseline | 39.1 (± 13.9) | | | |
| Day 2 | 42.0 (± 14.7) | | | |
| Day 4 | 47.5 (± 14.6) | | | |
| Day 6 | 49.7 (± 13.7) | | | |
| Day 8 | 50.0 (± 13.8) | | | |
| Day 15 | 51.8 (± 12.1) | | | |
| Day 29 | 49.1 (± 17.4) | | | |

| | | | | |
|---------|---------------|--|--|--|
| Day 57 | 49.0 (± 18.4) | | | |
| Day 92 | 51.8 (± 16.2) | | | |
| Day 180 | 54.1 (± 12.4) | | | |

Statistical analyses

No statistical analyses for this end point

Primary: Change in MRC sum sore over time

| | |
|-----------------|---|
| End point title | Change in MRC sum sore over time ^[5] |
|-----------------|---|

End point description:

The Medical Research Council (MRC) scale is a commonly used tool for assessing muscle strength. The resulting MRC sum score ranges from 60 (normal) to 0 (quadriplegic).

| | |
|----------------|---------|
| End point type | Primary |
|----------------|---------|

End point timeframe:

Change from Baseline to Different visits up to Day 180

Notes:

[5] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Not applicable, this was a single arm study.

| End point values | FAS | | | |
|--------------------------------------|----------------------|--|--|--|
| Subject group type | Subject analysis set | | | |
| Number of subjects analysed | 27 ^[6] | | | |
| Units: Score | | | | |
| arithmetic mean (standard deviation) | | | | |
| Day 2 | 2.9 (± 8.2) | | | |
| Day 4 | 8.4 (± 9.2) | | | |
| Day 6 | 10.3 (± 9.8) | | | |
| Day 8 | 10.7 (± 10.2) | | | |
| Day 15 | 11.2 (± 10.4) | | | |
| Day 29 | 10.0 (± 13.0) | | | |
| Day 57 | 9.9 (± 14.6) | | | |
| Day 92 | 12.7 (± 13.0) | | | |
| Day 180 | 15.0 (± 10.6) | | | |

Notes:

[6] - 26 patients analysed at Day 6 and Day 8

25 patients analysed at Day 15

Statistical analyses

No statistical analyses for this end point

Primary: R-ODS over time

| | |
|-----------------|--------------------------------|
| End point title | R-ODS over time ^[7] |
|-----------------|--------------------------------|

End point description:

The patients have rated their ability to perform different common activities using the Rasch-built overall disability score (R-ODS) questionnaire.

The resulting R-ODS ranges from 0 (most severe disability) to 100 (no disability at all).

| | |
|----------------|---------|
| End point type | Primary |
|----------------|---------|

End point timeframe:

Baseline to Day 360

Notes:

[7] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Not applicable, this was a single arm study.

| End point values | FAS | | | |
|--------------------------------------|----------------------|--|--|--|
| Subject group type | Subject analysis set | | | |
| Number of subjects analysed | 27 ^[8] | | | |
| Units: R-ODS | | | | |
| arithmetic mean (standard deviation) | | | | |
| Baseline | 23.7 (± 15.3) | | | |
| Day 8 | 41.9 (± 28.0) | | | |
| Day 15 | 46.2 (± 26.9) | | | |
| Day 29 | 52.6 (± 33.1) | | | |
| Day 57 | 57.2 (± 34.5) | | | |
| Day 92 | 63.5 (± 32.5) | | | |
| Day 180 | 70.0 (± 29.2) | | | |
| Day 360 | 73.8 (± 24.4) | | | |

Notes:

[8] - 26 patients analysed at Day 8, Day 57, Day 92, and Day 360

24 patients analysed at Day 15

Statistical analyses

No statistical analyses for this end point

Primary: Change in R-ODS over time

| | |
|--|--|
| End point title | Change in R-ODS over time ^[9] |
| End point description: | |
| The patients have rated their ability to perform different common activities using the Rasch-built overall disability score (R-ODS) questionnaire. | |
| The resulting R-ODS ranges from 0 (most severe disability) to 100 (no disability at all). This endpoint presents the change from baseline. A positive value indicates improvement. | |
| End point type | Primary |
| End point timeframe: | |
| From Baseline to Day 360 | |

Notes:

[9] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Not applicable, this was a single arm study.

| End point values | FAS | | | |
|--------------------------------------|----------------------|--|--|--|
| Subject group type | Subject analysis set | | | |
| Number of subjects analysed | 27 ^[10] | | | |
| Units: R-ODS | | | | |
| arithmetic mean (standard deviation) | | | | |
| Day 8 | 17.2 (± 22.3) | | | |
| Day 15 | 20.8 (± 21.4) | | | |
| Day 29 | 28.8 (± 25.3) | | | |
| Day 57 | 34.5 (± 26.5) | | | |
| Day 92 | 40.8 (± 24.6) | | | |

| | | | | |
|---------|---------------|--|--|--|
| Day 180 | 46.3 (± 22.7) | | | |
| Day 360 | 50.5 (± 19.3) | | | |

Notes:

[10] - 26 patients analysed at Day 8, Day 57, Day 92, and Day 360

24 patients analysed at Day 15

Statistical analyses

No statistical analyses for this end point

Primary: Days in Hospital

| | |
|-----------------|----------------------------------|
| End point title | Days in Hospital ^[11] |
|-----------------|----------------------------------|

End point description:

| | |
|----------------|---------|
| End point type | Primary |
|----------------|---------|

End point timeframe:

Baseline to Day 360

Notes:

[11] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Not applicable, this was a single arm study.

| End point values | Safety analysis set | | | |
|--------------------------------------|----------------------|--|--|--|
| Subject group type | Subject analysis set | | | |
| Number of subjects analysed | 30 | | | |
| Units: Days | | | | |
| arithmetic mean (standard deviation) | 32.5 (± 43.5) | | | |

Statistical analyses

No statistical analyses for this end point

Primary: Time in an ICU

| | |
|-----------------|--------------------------------|
| End point title | Time in an ICU ^[12] |
|-----------------|--------------------------------|

End point description:

| | |
|----------------|---------|
| End point type | Primary |
|----------------|---------|

End point timeframe:

From Screening to Day 180

Notes:

[12] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Not applicable, this was a single arm study.

| End point values | Safety analysis set | | | |
|-----------------------------|----------------------|--|--|--|
| Subject group type | Subject analysis set | | | |
| Number of subjects analysed | 30 | | | |
| Units: Patients | | | | |
| Admitted 0 days | 18 | | | |
| Admitted 2-11 days | 9 | | | |
| Admitted 106-113 days | 2 | | | |
| Admitted 172 days | 1 | | | |

Statistical analyses

No statistical analyses for this end point

Primary: Need for mechanical ventilation

| | |
|-----------------|---|
| End point title | Need for mechanical ventilation ^[13] |
|-----------------|---|

End point description:

| | |
|----------------|---------|
| End point type | Primary |
|----------------|---------|

End point timeframe:

Screening to Day 180

Notes:

[13] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Not applicable, this was a single arm study.

| End point values | Safety analysis set | | | |
|--|----------------------|--|--|--|
| Subject group type | Subject analysis set | | | |
| Number of subjects analysed | 30 | | | |
| Units: Patients | | | | |
| Screening | 0 | | | |
| Day 1 to Day 90 | 1 | | | |
| Day 5 to Day 102 | 1 | | | |
| Day 9 to Day 90 and Day 103 to Day 180 | 1 | | | |

Statistical analyses

No statistical analyses for this end point

Primary: Quality of Life over time

| | |
|-----------------|---|
| End point title | Quality of Life over time ^[14] |
|-----------------|---|

End point description:

The EQ-5D-5L questionnaire was completed by the patients. It consists of descriptive statements pertaining to 5 individual dimensions (mobility, self care, usual activities, pain/discomfort and anxiety/depression). The patient was asked to indicate his/her health state by ticking the box next to the most appropriate statement in each of the five dimensions. The EQ VAS records the patient's self-rated health on a vertical visual analogue scale where the endpoints are labelled 'The best health you

can image' and 'The worst health you can image'.

| | |
|--|---------|
| End point type | Primary |
| End point timeframe: | |
| From Day 8 to Day 360 | |
| Notes: | |
| [14] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. | |
| Justification: Not applicable, this was a single arm study. | |

| End point values | FAS | | | |
|--------------------------------------|----------------------|--|--|--|
| Subject group type | Subject analysis set | | | |
| Number of subjects analysed | 30 ^[15] | | | |
| Units: EQ-5D-5L VAS score | | | | |
| arithmetic mean (standard deviation) | | | | |
| Day 8 | 49.7 (± 23.7) | | | |
| Day 15 | 61.3 (± 24.8) | | | |
| Day 29 | 67.3 (± 21.0) | | | |
| Day 57 | 68.8 (± 25.1) | | | |
| Day 92 | 75.2 (± 23.9) | | | |
| Day 180 | 78.6 (± 20.6) | | | |
| Day 360 | 79.4 (± 18.6) | | | |

Notes:

[15] - 27 replied at D92 and D180

26 replied at D8 and D360

25 replied at D29 and D57

24 replied at D15

Statistical analyses

No statistical analyses for this end point

Primary: GBS DS - Time to improve by at least 2 grades

| | |
|---|---|
| End point title | GBS DS - Time to improve by at least 2 grades ^[16] |
| End point description: | |
| The GBS disability score is a scoring system used to assess the status of the patients with GBS. The score consists of the following grades: 0=Healthy, 1= Minor symptoms and capable of running, 2=Able to walk independently 10 meters or more but unable to run, 3=Able to walk more than 10 meters across an open space with help, 4=Bedridden or chair bound, 5=Needing mechanical ventilation, 6=Dead | |
| End point type | Primary |
| End point timeframe: | |
| Baseline to Day 360 | |
| Notes: | |
| [16] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. | |
| Justification: Not applicable, this was a single arm study. | |

| End point values | FAS | | | |
|--------------------------------------|----------------------|--|--|--|
| Subject group type | Subject analysis set | | | |
| Number of subjects analysed | 27 | | | |
| Units: Days | | | | |
| median (full range (min-max)) | | | | |
| Time to improve by at least 2 grades | 16.0 (8.0 to 92.0) | | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Pharmacokinetics (PK) - C_{max}, AUC, t_{1/2} (alfa), t_{1/2} (beta), CL, V_{ss}, and V_z

| | |
|-----------------|--|
| End point title | Pharmacokinetics (PK) - C _{max} , AUC, t _{1/2} (alfa), t _{1/2} (beta), CL, V _{ss} , and V _z |
|-----------------|--|

End point description:

C_{max}=Maximum observed plasma concentration of imlifidase following dosing

AUC=Area under the plasma concentration of imlifidase versus time curve

t_{1/2}α=Half-life initial phase

t_{1/2}β=Half-life terminal phase

CL=Clearance is a measure of the ability of the body to clear imlifidase from plasma

V_z=Volume of distribution of imlifidase during the elimination phase

V_{ss}=Volume of distribution at steady state

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

From dosing until Day 15

| End point values | PK/PD | | | |
|---|----------------------|--|--|--|
| Subject group type | Subject analysis set | | | |
| Number of subjects analysed | 16 ^[17] | | | |
| Units: See below: | | | | |
| geometric mean (geometric coefficient of variation) | | | | |
| C _{max} (µg/mL) | 5.5 (± 17.0) | | | |
| AUC (h×µg/mL) | 45.0 (± 54.9) | | | |
| t _{1/2} (h) initial phase (α) | 1.73 (± 0) | | | |
| t _{1/2} (h) terminal phase (β) | 30.6 (± 0) | | | |
| CL (mL/h/kg) | 5.6 (± 54.9) | | | |
| V _z (L/kg) | 0.3 (± 40.7) | | | |
| V _{ss} (L/kg) | 0.2 (± 41.1) | | | |

Notes:

[17] - C_{max} for all 16. All other for 9 who could be fitted to 2-compart model. Harmonic mean for t_{1/2}s.

Statistical analyses

No statistical analyses for this end point

Secondary: Pharmacodynamics - IgG level in serum over time

| | |
|-----------------|---|
| End point title | Pharmacodynamics - IgG level in serum over time |
|-----------------|---|

End point description:

The pharmacodynamic (PD) effect of imlifidase is assessed as the elimination of IgG. IgG is cleaved by

imlifidase in two steps, the first cut generates single-cleaved IgG (scIgG), and the second cut generates one F(ab')₂ fragment and one Fc fragment. The IgG concentration measured in serum using the MSD technology is the sum of intact IgG and scIgG and a decrease in the measured IgG concentration therefore represents complete cleavage of the IgG molecule to Fc and F(ab')₂ fragments. For the first 16 patients included in the trial a more frequent PD sampling schedule was conducted. After amending the protocol a less frequent PD sampling schedule was applied.

| | |
|----------------------------------|-----------|
| End point type | Secondary |
| End point timeframe: | |
| Day 1 (before dose) until Day 15 | |

| End point values | PK/PD | | | |
|--------------------------------------|----------------------|--|--|--|
| Subject group type | Subject analysis set | | | |
| Number of subjects analysed | 30 ^[18] | | | |
| Units: mg/mL | | | | |
| arithmetic mean (standard deviation) | | | | |
| Day 1, pre-dose | 10.8 (± 4.5) | | | |
| Day 2, 24 hours after dose | 1.3 (± 3.5) | | | |
| Day 3, before IVIg administration | 1.6 (± 3.5) | | | |
| Day 4, before IVIg administration | 8.6 (± 2.3) | | | |
| Day 5, before IVIg administration | 14.3 (± 1.9) | | | |
| Day 6, before IVIg administration | 18.1 (± 4.0) | | | |
| Day 7, before IVIg administration | 20.8 (± 5.5) | | | |
| Day 8 | 28.6 (± 9.2) | | | |
| Day 15 | 22.5 (± 10.0) | | | |

Notes:

[18] - 16 patients analysed at Day 4, Day 5, Day 6, and Day 7 as described above.

Statistical analyses

No statistical analyses for this end point

Secondary: Immunogenicity - Anti-implifidase antibodies (ADA) over time

| | |
|---|--|
| End point title | Immunogenicity - Anti-implifidase antibodies (ADA) over time |
| End point description: | |
| Anti-implifidase IgG antibodies (ADA) in serum. | |
| End point type | Secondary |
| End point timeframe: | |
| Predose until Day 180 | |

| End point values | Safety analysis set | | | |
|--------------------------------------|----------------------|--|--|--|
| Subject group type | Subject analysis set | | | |
| Number of subjects analysed | 30 ^[19] | | | |
| Units: mg/mL | | | | |
| arithmetic mean (standard deviation) | | | | |
| Day 1, pre-dose | 11.1 (± 17.1) | | | |
| Day 2, 24 h after dose | 4.0 (± 9.6) | | | |

| | | | | |
|-----------------|------------------------|--|--|--|
| Day 3, pre-IVIg | 4.5 (\pm 12.2) | | | |
| Day 8 | 474.5 (\pm 909.0) | | | |
| Day 15 | 2811.9 (\pm 3772.6) | | | |
| Day 29 | 2120.1 (\pm 2813.7) | | | |
| Day 57 | 1060.3 (\pm 1086.5) | | | |
| Day 92 | 722.1 (\pm 806.8) | | | |
| Day 180 | 336.0 (\pm 318.9) | | | |

Notes:

[19] - 28 patients have been analysed at Day 29, Day 57, Day 92, and Day 180

Statistical analyses

No statistical analyses for this end point

Secondary: Pharmacokinetics (PK) - Tmax

| | |
|--|------------------------------|
| End point title | Pharmacokinetics (PK) - Tmax |
| End point description: | |
| Tmax = Time point for maximum observed plasma concentration of imlifidase following dosing | |
| End point type | Secondary |
| End point timeframe: | |
| From dosing until Day 15 | |

| End point values | PK/PD | | | |
|-------------------------------|----------------------|--|--|--|
| Subject group type | Subject analysis set | | | |
| Number of subjects analysed | 16 | | | |
| Units: hours | | | | |
| median (full range (min-max)) | | | | |
| Tmax (h) | 0.74 (0.47 to 2.07) | | | |

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

Adverse events (AEs) were collected for 1 year (i.e., from the timepoint the patient signed the informed consent form (ICF) until Day 360.

Adverse event reporting additional description:

AEs were either spontaneously reported, reported in response to an open question, or revealed by observation.

A TEAE is any AE occurring after imlifidase and within 29 days. The listed non-serious AEs presents TEAEs only.

18 SAEs have been reported, 9 of which were TEAEs. All SAEs are listed.

| | |
|-----------------|------------|
| Assessment type | Systematic |
|-----------------|------------|

Dictionary used

| | |
|--------------------|--------|
| Dictionary name | MedDRA |
| Dictionary version | 21.1 |

Reporting groups

| | |
|-----------------------|---------------------|
| Reporting group title | Safety Analysis Set |
|-----------------------|---------------------|

Reporting group description:

All 30 patients who have received imlifidase in the trial.

25 out of 30 patients were affected by non-serious treatment emergent adverse events (TEAEs).

28 out of 30 patients were affected by non-serious AEs, including pre-treatment and post-treatment emergent events.

5 out of 30 patients were affected by treatment emergent SAEs.

7 out of 30 patients were affected by SAEs including pre-treatment and post-treatment emergent events.

| Serious adverse events | Safety Analysis Set | | |
|---|--|--|--|
| Total subjects affected by serious adverse events | | | |
| subjects affected / exposed | 7 / 30 (23.33%) | | |
| number of deaths (all causes) | 1 | | |
| number of deaths resulting from adverse events | 1 | | |
| Investigations | | | |
| False positive investigation result | Additional description: Covid false positive | | |
| subjects affected / exposed | 1 / 30 (3.33%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Nervous system disorders | | | |
| Neuropathy peripheral | | | |
| subjects affected / exposed | 3 / 30 (10.00%) | | |
| occurrences causally related to treatment / all | 0 / 4 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Central nervous system inflammation | | | |

| | | | |
|---|----------------|--|--|
| subjects affected / exposed | 1 / 30 (3.33%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Demyelination | | | |
| subjects affected / exposed | 1 / 30 (3.33%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 1 | | |
| Gastrointestinal disorders | | | |
| Gastroduodenal ulcer | | | |
| subjects affected / exposed | 1 / 30 (3.33%) | | |
| occurrences causally related to treatment / all | 1 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Oesophagitis | | | |
| subjects affected / exposed | 1 / 30 (3.33%) | | |
| occurrences causally related to treatment / all | 1 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Respiratory, thoracic and mediastinal disorders | | | |
| Respiratory failure | | | |
| subjects affected / exposed | 1 / 30 (3.33%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Pulmonary embolism | | | |
| subjects affected / exposed | 1 / 30 (3.33%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Bronchospasm | | | |
| subjects affected / exposed | 1 / 30 (3.33%) | | |
| occurrences causally related to treatment / all | 1 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Psychiatric disorders | | | |
| Adjustment disorder with depressed mood | | | |

| | | | |
|---|----------------|--|--|
| subjects affected / exposed | 1 / 30 (3.33%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Renal and urinary disorders | | | |
| Acute kidney injury | | | |
| subjects affected / exposed | 1 / 30 (3.33%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Infections and infestations | | | |
| Escherichia bacteraemia | | | |
| subjects affected / exposed | 1 / 30 (3.33%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Pneumonia | | | |
| subjects affected / exposed | 2 / 30 (6.67%) | | |
| occurrences causally related to treatment / all | 0 / 2 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Influenza | | | |
| subjects affected / exposed | 1 / 30 (3.33%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |

Frequency threshold for reporting non-serious adverse events: 3.3 %

| Non-serious adverse events | Safety Analysis Set | | |
|---|---------------------|--|--|
| Total subjects affected by non-serious adverse events | | | |
| subjects affected / exposed | 25 / 30 (83.33%) | | |
| Vascular disorders | | | |
| Hypertension | | | |
| subjects affected / exposed | 6 / 30 (20.00%) | | |
| occurrences (all) | 6 | | |
| Deep vein thrombosis | | | |
| subjects affected / exposed | 1 / 30 (3.33%) | | |
| occurrences (all) | 1 | | |
| Hypotension | | | |

| | | | |
|--|---|--|--|
| subjects affected / exposed occurrences (all) | 1 / 30 (3.33%) 1 | | |
| General disorders and administration site conditions Pyrexia subjects affected / exposed occurrences (all) Chills subjects affected / exposed occurrences (all) Pain subjects affected / exposed occurrences (all) Vessel puncture site phlebitis subjects affected / exposed occurrences (all) | 3 / 30 (10.00%) 3 1 / 30 (3.33%) 1 1 / 30 (3.33%) 1 1 / 30 (3.33%) 1 | | |
| Immune system disorders Drug hypersensitivity subjects affected / exposed occurrences (all) | 1 / 30 (3.33%) 1 | | |
| Reproductive system and breast disorders Vulvovaginal pruritus subjects affected / exposed occurrences (all) | 1 / 30 (3.33%) 1 | | |
| Respiratory, thoracic and mediastinal disorders Respiratory failure subjects affected / exposed occurrences (all) Dyspnoea subjects affected / exposed occurrences (all) Pneumonia aspiration subjects affected / exposed occurrences (all) Pulmonary mass | 1 / 30 (3.33%) 1 1 / 30 (3.33%) 1 1 / 30 (3.33%) 1 1 / 30 (3.33%) 1 | | |

| | | | |
|---|---|--|--|
| <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Rales</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Stridor</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> | <p>1 / 30 (3.33%)</p> <p>1</p> <p>1 / 30 (3.33%)</p> <p>1</p> <p>1 / 30 (3.33%)</p> <p>1</p> | | |
| <p>Psychiatric disorders</p> <p>Anxiety</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Insomnia</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Delirium</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Hallucination</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Hallucination, visual</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> | <p>6 / 30 (20.00%)</p> <p>6</p> <p>2 / 30 (6.67%)</p> <p>2</p> <p>1 / 30 (3.33%)</p> <p>1</p> <p>1 / 30 (3.33%)</p> <p>1</p> <p>1 / 30 (3.33%)</p> <p>1</p> | | |
| <p>Investigations</p> <p>Alanine aminotransferase increased</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>C-reactive protein increased</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Liver function test abnormal</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>White blood cell count increased</p> | <p>3 / 30 (10.00%)</p> <p>3</p> <p>2 / 30 (6.67%)</p> <p>2</p> <p>2 / 30 (6.67%)</p> <p>2</p> | | |

| | | | |
|--|----------------|--|--|
| subjects affected / exposed | 2 / 30 (6.67%) | | |
| occurrences (all) | 3 | | |
| Aspartate aminotransferase increased | | | |
| subjects affected / exposed | 1 / 30 (3.33%) | | |
| occurrences (all) | 1 | | |
| Body temperature increased | | | |
| subjects affected / exposed | 1 / 30 (3.33%) | | |
| occurrences (all) | 1 | | |
| Gamma-glutamyltransferase increased | | | |
| subjects affected / exposed | 1 / 30 (3.33%) | | |
| occurrences (all) | 1 | | |
| Glomerular filtration rate decreased | | | |
| subjects affected / exposed | 1 / 30 (3.33%) | | |
| occurrences (all) | 1 | | |
| Haematocrit decreased | | | |
| subjects affected / exposed | 1 / 30 (3.33%) | | |
| occurrences (all) | 1 | | |
| Haemoglobin decreased | | | |
| subjects affected / exposed | 1 / 30 (3.33%) | | |
| occurrences (all) | 1 | | |
| Staphylococcus test positive | | | |
| subjects affected / exposed | 1 / 30 (3.33%) | | |
| occurrences (all) | 1 | | |
| Troponin I increased | | | |
| subjects affected / exposed | 1 / 30 (3.33%) | | |
| occurrences (all) | 1 | | |
| Weight decreased | | | |
| subjects affected / exposed | 1 / 30 (3.33%) | | |
| occurrences (all) | 1 | | |
| Injury, poisoning and procedural complications | | | |
| Fall | | | |
| subjects affected / exposed | 1 / 30 (3.33%) | | |
| occurrences (all) | 1 | | |
| Infusion related reaction | | | |

| | | | |
|---|----------------------|--|--|
| subjects affected / exposed occurrences (all) | 1 / 30 (3.33%) 1 | | |
| Cardiac disorders | | | |
| Sinus tachycardia subjects affected / exposed occurrences (all) | 2 / 30 (6.67%) 2 | | |
| Tachycardia subjects affected / exposed occurrences (all) | 1 / 30 (3.33%) 1 | | |
| Nervous system disorders | | | |
| Neuropathy peripheral subjects affected / exposed occurrences (all) | 3 / 30 (10.00%) 3 | | |
| Facial paralysis subjects affected / exposed occurrences (all) | 2 / 30 (6.67%) 2 | | |
| Headache subjects affected / exposed occurrences (all) | 1 / 30 (3.33%) 1 | | |
| Presyncope subjects affected / exposed occurrences (all) | 1 / 30 (3.33%) 1 | | |
| Vocal cord paresis subjects affected / exposed occurrences (all) | 1 / 30 (3.33%) 1 | | |
| Blood and lymphatic system disorders | | | |
| Lymphopenia subjects affected / exposed occurrences (all) | 1 / 30 (3.33%) 1 | | |
| Normocytic anaemia subjects affected / exposed occurrences (all) | 1 / 30 (3.33%) 1 | | |
| Eye disorders | | | |
| Vision blurred subjects affected / exposed occurrences (all) | 1 / 30 (3.33%) 1 | | |
| Vitreous floaters | | | |

| | | | |
|--|---------------------|--|--|
| subjects affected / exposed occurrences (all) | 1 / 30 (3.33%) 1 | | |
| Gastrointestinal disorders | | | |
| Constipation | | | |
| subjects affected / exposed | 9 / 30 (30.00%) | | |
| occurrences (all) | 9 | | |
| Abdominal pain upper | | | |
| subjects affected / exposed | 1 / 30 (3.33%) | | |
| occurrences (all) | 1 | | |
| Cheilitis | | | |
| subjects affected / exposed | 1 / 30 (3.33%) | | |
| occurrences (all) | 1 | | |
| Gastrointestinal motility disorder | | | |
| subjects affected / exposed | 1 / 30 (3.33%) | | |
| occurrences (all) | 1 | | |
| Intestinal pseudo-obstruction | | | |
| subjects affected / exposed | 1 / 30 (3.33%) | | |
| occurrences (all) | 1 | | |
| Hepatobiliary disorders | | | |
| Hepatocellular injury | | | |
| subjects affected / exposed | 3 / 30 (10.00%) | | |
| occurrences (all) | 3 | | |
| Cholestasis | | | |
| subjects affected / exposed | 1 / 30 (3.33%) | | |
| occurrences (all) | 1 | | |
| Skin and subcutaneous tissue disorders | | | |
| Night sweats | | | |
| subjects affected / exposed | 1 / 30 (3.33%) | | |
| occurrences (all) | 1 | | |
| Renal and urinary disorders | | | |
| Acute kidney injury | | | |
| subjects affected / exposed | 1 / 30 (3.33%) | | |
| occurrences (all) | 1 | | |
| Prerenal failure | | | |
| subjects affected / exposed | 1 / 30 (3.33%) | | |
| occurrences (all) | 1 | | |
| Urinary retention | | | |

| | | | |
|--|---|--|--|
| subjects affected / exposed occurrences (all) | 1 / 30 (3.33%) 1 | | |
| Endocrine disorders Autoimmune thyroiditis subjects affected / exposed occurrences (all) Hypothyroidism subjects affected / exposed occurrences (all) Inappropriate antidiuretic hormone secretion subjects affected / exposed occurrences (all) | 1 / 30 (3.33%) 1 1 / 30 (3.33%) 1 1 / 30 (3.33%) 1 | | |
| Musculoskeletal and connective tissue disorders Arthralgia subjects affected / exposed occurrences (all) Pain in extremity subjects affected / exposed occurrences (all) Spinal pain subjects affected / exposed occurrences (all) | 1 / 30 (3.33%) 1 1 / 30 (3.33%) 1 1 / 30 (3.33%) 1 | | |
| Infections and infestations Pneumonia subjects affected / exposed occurrences (all) Urinary tract infection bacterial subjects affected / exposed occurrences (all) Corona virus infection subjects affected / exposed occurrences (all) Cytomegalovirus infection subjects affected / exposed occurrences (all) Epstein-Barr virus infection | 3 / 30 (10.00%) 3 2 / 30 (6.67%) 2 1 / 30 (3.33%) 1 1 / 30 (3.33%) 1 | | |

| | | | |
|--------------------------------------|-----------------|--|--|
| subjects affected / exposed | 1 / 30 (3.33%) | | |
| occurrences (all) | 1 | | |
| Erysipelas | | | |
| subjects affected / exposed | 1 / 30 (3.33%) | | |
| occurrences (all) | 1 | | |
| Escherichia urinary tract infection | | | |
| subjects affected / exposed | 1 / 30 (3.33%) | | |
| occurrences (all) | 1 | | |
| Oral candidiasis | | | |
| subjects affected / exposed | 1 / 30 (3.33%) | | |
| occurrences (all) | 1 | | |
| Oral herpes | | | |
| subjects affected / exposed | 1 / 30 (3.33%) | | |
| occurrences (all) | 1 | | |
| Pneumonia pseudomonal | | | |
| subjects affected / exposed | 1 / 30 (3.33%) | | |
| occurrences (all) | 1 | | |
| Sepsis | | | |
| subjects affected / exposed | 1 / 30 (3.33%) | | |
| occurrences (all) | 1 | | |
| Urinary tract infection | | | |
| subjects affected / exposed | 1 / 30 (3.33%) | | |
| occurrences (all) | 1 | | |
| Urinary tract infection enterococcal | | | |
| subjects affected / exposed | 1 / 30 (3.33%) | | |
| occurrences (all) | 1 | | |
| Metabolism and nutrition disorders | | | |
| Hyponatraemia | | | |
| subjects affected / exposed | 5 / 30 (16.67%) | | |
| occurrences (all) | 5 | | |
| Hypokalaemia | | | |
| subjects affected / exposed | 2 / 30 (6.67%) | | |
| occurrences (all) | 2 | | |
| Folate deficiency | | | |
| subjects affected / exposed | 1 / 30 (3.33%) | | |
| occurrences (all) | 1 | | |

| | | | |
|-----------------------------|----------------|--|--|
| Gout | | | |
| subjects affected / exposed | 1 / 30 (3.33%) | | |
| occurrences (all) | 1 | | |
| Hyperglycaemia | | | |
| subjects affected / exposed | 1 / 30 (3.33%) | | |
| occurrences (all) | 1 | | |
| Hypophosphataemia | | | |
| subjects affected / exposed | 1 / 30 (3.33%) | | |
| occurrences (all) | 1 | | |
| Vitamin B1 deficiency | | | |
| subjects affected / exposed | 1 / 30 (3.33%) | | |
| occurrences (all) | 1 | | |

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

| Date | Amendment |
|------------------|--|
| 14 November 2019 | <ul style="list-style-type: none">- Updates to the SRC composition- Modification of 2 eligibility criteria- More detailed guidance about IVIg treatment |
| 09 October 2020 | Patients with a positive PCR test for SARS-CoV-2 (Covid-19) should be excluded from the trial before restarting the trial. In addition, patients with an ongoing infection were to be excluded from the trial regardless if the infection required treatment or not. |
| 11 June 2021 | <ul style="list-style-type: none">- Minor modifications to the screening procedures were introduced (SARS-CoV-2 PCR test results if done at hospital admission could be used), thus minimising the risk of unnecessary delay of GBS treatment. |
| 31 January 2022 | <ul style="list-style-type: none">- PK sampling and ECG data collection were removed from the protocol as available data were deemed sufficient.- A less frequent sampling schedule was introduced- Addition of safety sections describing overdose and adverse events of special interest (AESIs).- Change in CRO responsible for SAE/suspected unexpected serious adverse reaction (SUSAR) reporting.- Prohibited therapies updated and clarified. |
| 27 June 2023 | <ul style="list-style-type: none">- To avoid delay in the reporting of the results of the single arm trial, the planned comparison to an externally matched cohort of GBS subjects will be outlined in a separate study protocol- To ensure comparison of relevant endpoints in the non-interventional study (matched cohort of GBS subjects) some endpoints were updated or added to the trial protocol. The objective, endpoints, and statistical sections were updated to reflect these changes.- To ensure the trial results can be properly evaluated and clinically interpreted, additional baseline and disease characteristic data were added to the protocol. These data were to be collected from the patient's medical records. |

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? Yes

| Date | Interruption | Restart date |
|------|--------------|--------------|
|------|--------------|--------------|

| | | |
|---------------|--|-------------------|
| 01 March 2020 | <p>This trial started in November 2019 and was completed in February 2024, which included the period during which the Covid-19 pandemic was ongoing in the countries with participating trial sites. In March 2020 the SRC recommended Hansa Biopharma to temporarily halt the enrolment of new patients into the trial due to the pandemic. The already included patients in the trial at the timepoint for halt of enrolment continued in the trial according to protocol.</p> <p>In September 2020, an ad-hoc SRC meeting was held to discuss restart of enrolment into the trial. The SRC members agreed that recruitment of patients in the trial could restart on a site-by-site basis after discussion with and confirmation by each principal investigator after amending the protocol to exclude patients with a positive PCR test for SARS-CoV-2 (Covid-19).</p> | 30 September 2020 |
|---------------|--|-------------------|

Notes:

Limitations and caveats

None reported